[Dynamic changes of hepatitis B virus during treatment with lamivudine versus lamivudine plus famciclovir].
OBJECTIVE
To study whether combination therapy with lamivudine (LAM) and famciclovir (FCV) is effective for treatment of Chinese chronic HBV infection.


METHODS
Chronic hepatitis B-infected patients treated with either LAM (n=9, 150 mg daily for 12 weeks) or LAM plus FCV (n=12, 150 mg LAM daily plus 500 mg FCV daily for 12 weeks). Serial serum HBV DNA were determined. A mathematical model was applied to analyze the dynamics of viral clearance.


RESULTS
HBV clearance from patients treated with LAM was biphasic attenuation with mean antiviral efficacy of 0.94 while a combination therapy with LAM and FCV displayed an increased mean antiviral efficacy of 0. 988. There was an increased magnitude of the first phase of clearance from 1.1 log(10) to 1.9 log(10). Mean log(10) HBV viral decline were 1.8A0.2 for LAM treated group and 2.5A0.8 for combination group.


CONCLUSIONS
Combination therapy of LAM and FCV has higher efficacy than LAM alone in suppressing HBV replication in Chinese chronic HBeAg-positive carriers.
Hou
J
J
Department of Infectious Diseases, Nanfang Hospital, Guangzhou 510515, China.
Fen
X
X
Nie
Z
Z
D015075:2-Aminopurine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D000077595:Famciclovir; D005260:Female; D006515:Hepatitis B virus / Q000187:drug effects / Q000302:isolation & purification; D019694:Hepatitis B, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D019259:Lamivudine; D015075:2-Aminopurine; D000077595:Famciclovir